A randomized controlled trial of ProRoot MTA, OrthoMTA and RetroMTA for pulpotomy in primary molars


    loading  Checking for direct PDF access through Ovid

Abstract

OBJECTIVES:The aim of this study was to determine the clinical efficacy of the newly developed OrthoMTA and RetroMTA, compared to conventionally used ProRoot MTA, for pulpotomy in primary teeth.MATERIAL AND METHODS:In this randomized clinical trial, 151 molars from 102 children, who met the inclusion criteria and were 3–10 years old, were enrolled. Ultimately, 143 teeth were divided in a randomized, single-blind manner into three groups according to the planned treatment: RetroMTA (n=49 teeth), OrthoMTA (n=47 teeth) or ProRoot MTA (n=47 teeth). Clinical and radiographic follow-up examinations were conducted at 3, 6 and 12 months postoperatively.RESULTS:By the end of the study period, 109 teeth were evaluated at 12 months. The radiographic success rates in these three groups were 100%, 94.7% and 94.7%, respectively; the corresponding clinical success rates were 100%, 97.4% and 100%. The Kaplan–Meier survival function curves relative to clinical and radiographic cumulative survival rates did not differ significantly between the three groups.CONCLUSIONS:The success rates of RetroMTA, OrthoMTA and ProRoot MTA are indistinguishable, indicating that pulpotomy can be carried out successfully in primary molars with the newly developed materials.

    loading  Loading Related Articles